Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

• Published in: EBioMedicine 2021-10, Vol.72, p.103581, Article 103581
• Main Authors: Sormani, Maria Pia, Inglese, Matilde, Carmisciano, Luca, Laroni, Alice, Lapucci, Caterina, Serrati, Carlo, Gandoglia, Ilaria, Tassinari, Tiziana, Perego, Germana, Brichetto, Giampaolo, Mannironi, Antonio, Stromillo, Maria Laura, Cordioli, Cinzia, Landi, Doriana, Clerico, Marinella, Frau, Jessica, Ferrò, Maria Teresa, Di Sapio, Alessia, Pasquali, Livia, Marinelli, Fabiana, Callari, Graziella, Iodice, Rosa, Liberatore, Giuseppe, Caleri, Francesca, Repice, Anna Maria, Cordera, Susanna, Battaglia, Mario Alberto, Salvetti, Marco, Franciotta, Diego, Maglione, Alessandro, Signori, Alessio, Nicoletti, Carolina Gabri, Mancinelli, Chiara Rosa, Bezzini, Daiana, Carmagnini, Daniele, Brogi, Davide, Orazio, Eduardo Nobile, Cocco, Eleonora, Signoriello, Elisabetta, Nako, Enri, Assandri, Ester, Baldi, Federica, Ansaldi, Filippo, Bovis, Francesca, Siciliano, Gabriele, Cola, Gaia, Icardi, Giancarlo, bellucci, gianmarco, Marfia, Girolama Alessandra, Vazzoler, Giulia, Schiavetti, Irene, Sticchi, Laura, Lorefice, Lorena, Manzino, Marcello, Bragadin, Margherita Monti, Buscarinu, Maria Chiara, Gagliardi, Maria, Rilla, Maria Teresa, Ponzano, Marta, Fronza, Marzia, Sette, Massimo Del, Bedognetti, Michele, Ulivelli, Monica, De Rossi, Nicola, De Stefano, Nicola, Gazzola, Paola, Bigi, Rachele, Dubbioso, Raffaele, Reniè, Roberta, Fabbri, Sabrina, Rasia, Sarah, Rolla, Simona, Platzgummer, Stefan, Carlini, Valentina
• Format: Article
• Language: English
• Subjects: Coronavirus; Immunomodulatory therapies; Multiple sclerosis; Research Paper
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2021.103581

In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects immune response to antigens. Therefore, post-vaccination serological assessments are needed to evaluate the effect of the vaccine on SARS-CoV-2 antibody response. We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination with mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). A blood collection before the first vaccine dose and 4 weeks after the second dose was planned, with a centralized serological assessment (electrochemiluminescence immunoassay, ECLIA, Roche-Diagnostics). The log-transform of the antibody levels was analyzed by multivariable linear regression. 780 pwMS (76% BNT162b2 and 24% mRNA-1273) had pre- and 4-week post-vaccination blood assessments. 87 (11·2%) were untreated, 154 (19·7%) on ocrelizumab, 25 (3·2%) on rituximab, 85 (10·9%) on fingolimod, 25 (3·2%) on cladribine and 404 (51·7%) on other DMTs. 677 patients (86·8%) had detectable post-vaccination SARS-CoV-2 antibodies. At multivariable analysis, the antibody levels of patients on ocrelizumab (201-fold decrease (95%CI=128–317), p